当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2018-03-17 , DOI: 10.1016/j.ejmech.2018.03.032
Jiyu Jin , Chunxiao Miao , Zhilong Wang , Wanli Zhang , Xiongwen Zhang , Xin Xie , Wei Lu

β-adrenergic receptors (β-ARs) are broadly distributed in various tissues and regulate a panel of important physiological functions and disease states including cancer. Above all, β3-adrenergic receptor (β3-AR) plays a significant role in regulating lipolysis and thermogenesis in adipose tissue. In this study, we designed and synthesized a series of novel L-748,337 derivatives as selective human β3-AR antagonists. Among all the tested L-748,337 analogs, compound 23d was found to display 23-fold more potent β3-AR antagonist activity (EC50 = 0.5117 nM) than L-748,337 (EC50 = 11.91 nM). In vivo, compound 23d could alleviate weight loss and inhibit tumor growth in C26 tumor cachexia animal model.



中文翻译:

设计和芳氧基丙醇的合成作为β 3在癌症和脂肪分解-肾上腺素能受体拮抗剂

β-肾上腺素能受体(β-ARs)广泛分布在各种组织中,并调节一系列重要的生理功能和疾病状态,包括癌症。首先,β 3肾上腺素能受体(β 3 -AR)发挥了在脂肪组织中脂肪分解调节和产热一个显著的作用。在这项研究中,我们设计并合成了一系列新的L-748337衍生物作为选择性人β 3 -AR拮抗剂。在所有被测试的L-748337类似物,化合物23d中被发现显示23倍更有效的β 3 -AR拮抗剂活性(EC 50  = 0.5117 nM)的比L-748337(EC 50  = 11.91 nM)的。体内化合物23d 在C26肿瘤恶病质动物模型中可以减轻体重并抑制肿瘤生长。

更新日期:2018-03-17
down
wechat
bug